



**Office of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

February 09, 2010 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)

- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
 - Pharmacy Best Practices and Cost Containment Report 2010

- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments
 - DUR Board Meeting Schedule

- 5. Follow-up Items from Previous Meeting** **7:20 - 7:20**
 - No follow-up items

- 6. Clinical Update: Drug Reviews** **7:20 – 7:50**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Acuvail[®] (ketorolac) Ophthalmic Solution
 - Asacol HD[®] (mesalamine) Delayed Release Tablet
 - Edular[®] (zolpidem tartrate) Sublingual Tablet

 - Full New Drug Reviews**
 - Cetraxal[®] (ciprofloxacin) Otic Solution
 - Embeda[®] (morphinesulfate/naltrexone hydrochloride) Capsule (long acting)
 - Intuniv[®] (guanfacine) Extended Release Tablet

- 7. Therapeutic Drug Classes – Periodic Review** **7:50 – 8:00**
(with selected new drug or new drug dosage form reviews)
(Public comment prior to Board action)
Class review documents available on OVHA web site 02/09/2010 @ 12 Noon
 - Scabicides and Pediculicides (includes overview of Ulesfia[®] (benzyl alcohol 5% lotion))

- 8. New Managed Therapeutic Drug Classes** **8:00 – 8:10**
(Public comment prior to Board action)
Class review documents available on OVHA web site 02/09/2010 @ 12 Noon
 - Pulmonary Arterial Hypertension Agents

9. Review of Newly-Developed/Revised Clinical Coverage Criteria **8:10 – 8:20**

(Public comment prior to Board action)

- Anti-Diabetics: Peptide Hormones (Byetta[®])
- Gastrointestinals: Inflammatory Bowel Agents (Oral and Rectal Products)
- Suboxone[®]/Subutex[®] (buprenorphine)

10. RetroDUR/Quality Assurance Analysis **8:20 - 8:40**

- Cost Savings/Clinical Analysis of Prior Initiatives
 - Specialty Pharmacy – Hepatitis C and Growth Hormone

11. Updated New-to-Market Drug Monitoring Log (Consent Agenda Topic) **8:40 - 8:40**

- Now on OVHA website

12. General Announcements **8:40 – 8:55**

- Antipsychotics in Children – NY Times article

Selected FDA Safety Alerts

- Meridia[®] (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review
- Norpramin[®] (desipramine) – Sudden Cardiac Death
- Valproate – Neural Tube Birth Defects
- Voltaren Gel[®] (diclofenac) - Hepatic Effects
- Zyprexa[®] (olanzapine): Use in Adolescents

13. Adjourn **9:00**